© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
The rationale behind the use of lutetium-177-PSMA-617, a targeted radioligand therapy, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.
July 23rd 2021
Dr Scott T. Tagawa describes what prostate-specific membrane antigen (PSMA) is and explains its evolving role as a diagnostic, prognostic and therapeutic target in patients with advanced prostate cancer.
A discussion on the sensitivity and specificity of an emerging imaging modality, PSMA PET, in advanced prostate cancer.
An overview of safety and efficacy data presented at ASCO 2021 from the phase III VISION study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
July 30th 2021
Scott T. Tagawa, MD, MS, FACP, reviews implications for treating prostate-specific membrane antigen (PSMA) -positive advanced prostate cancer with lutetium-177–PSMA-617 based on results of the phase III VISION study and additional trials in the pipeline.
Scott T. Tagawa, MD, MS, FACP, discusses integration of prostate-specific membrane antigen [PSMA] positron emission tomography [PET] imaging into community practice to help identify potential candidates for PSMA-targeted radioligand therapy.